| Active substance | vorasidenib |
| Holder | Servier Belux |
| Status | Running |
| Indication | treatment of predominantly non-enhancing grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing >40kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy |
| Public documents | |
| Last update | 12/02/2026 |